Next Article in Journal
Humoral Response after a Fourth Dose with mRNA-1273 in Healthcare Workers with and without a History of SARS-CoV-2 Infection and Previously Vaccinated with Two Doses of BBIBP-CorV Plus BNT162b2 Vaccine
Previous Article in Journal
Effectiveness and Safety of Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) among Healthcare Workers: A Seven-Month Follow-Up Study at Fifteen Central Hospitals
Previous Article in Special Issue
The Clinical Effectiveness and Safety of Vaccinations against COVID-19 in HIV-Positive Patients: Data from Observational Study in Poland
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 11
Issue 5
10.3390/vaccines11050893
Review Report
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Article
Peer-Review Record

Effectiveness and Safety of SARS-CoV-2 Vaccination in HIV-Infected Patients—Real-World Study

Vaccines 2023, 11(5), 893; https://doi.org/10.3390/vaccines11050893
by Monika Bociąga-Jasik 1,2,*, Martyna Lara 2, Aleksandra Raczyńska 2, Barbara Wizner 3, Stanisław Polański 4, Ewa Mlicka-Kowalczyk 4, Aleksander Garlicki 1,2 and Marek Sanak 4
Reviewer 1:
Mohammad Kamran
Reviewer 2:
Saumya Anang
Vaccines 2023, 11(5), 893; https://doi.org/10.3390/vaccines11050893
Submission received: 15 March 2023 / Revised: 18 April 2023 / Accepted: 21 April 2023 / Published: 24 April 2023
(This article belongs to the Special Issue HIV Infection and Vaccination)

Round 1

Reviewer 1 Report

In the article entitled "Effectiveness and safety of SARS-CoV-2 vaccination in HIV infected patients- real-world study" by Bociąga-Jasik M et al; analyzed the effectiveness of SARS-CoV-2 vaccines in HIV patients and found that mRNA vaccines work better and generated both cellular and humoral responses in higher degree compared to non mRNA vaccines. Study also finds that elderly patients with comorbidities did not respond well to both vaccines. The mRNA vaccines were also shown higher IgG and IFN-Y compared to vector-based vaccines. This manuscript will be able to fill the gaps in the understanding of vaccine responses in HIV patients and will help to develop vaccines for these minority groups in future. 

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Reviewer 2 Report

The authors have studied the effectiveness and saftety of SARS -CoV-2 vaccines on patients infected with HIV. Though the study is informative and shows a sign of relief among HIV infected inviduals, I have the following suggestions/comments:

1. As the authors have mentioned already, control group is missing. The lack of control group overall makes the study redundant.

2. The authors have concluded mRNA-1273 vaccine appears to be more effective. However the sample size is too small to reach to any conclusion from this study. Though the authors claim that their observation correlates with other studies, I would still suggest that the sample size needs to be increased before reaching to any such conclusion.

3. The interferon-gamma release assay can be affected by HIV infection. I am not very convinced if this assay can be used to assess cell mediated immunity in HIV infected patients. The ideal condition would be to compare the interferon gamma release before and after vaccination.

4. If the duration since SARS-CoV-2 vaccination was taken into the account for each vaccine category? If the booster doses were taken into account?

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Round 2

Reviewer 2 Report

The authors have either made the suggested changes or have explained the short comings of the study that makes the manuscript easy to read and convincing.

Back to TopTop